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ABSTRACT
Objective: We evaluated the prevalence of glutamic acid decarboxylase (GADA) and tyrosine 
phosphatase-protein antibodies (IA2A), their titers and their relation to first phase insulin response 
(FPIR) and glucose tolerance in autoimmune thyroid diseases (ATDs) patients. Subjects and methods: 
Graves’ disease (GD; n = 181) and Hashimoto’s thyroiditis (HT; n = 143) patients in addition to healthy 
controls (n = 93) were studied. Secondly, FPIR and oral glucose tolerance tests (OGTT) were performed 
in 11 anti-pancreatic islet–cell (+) and in 20 anti-pancreatic–cell (-) patients. Results: There was a non 
significant trend for higher prevalence of GADA positivity in GD vs HT (7.2% vs 2% p = 0.06), but the 
GADA titers were higher in HT. We also did not find a significant difference in IA2 prevalence (0.7% vs 
0.0%) between these two groups or compared to the control group. In the subsequent analysis, low 
FPIR was found in 10% of these patients but without statistical difference for OGTT between pancreatic 
antibody–positive and –negative patients. Conclusion: A trend for greater prevalence of GADA was 
observed for GD patients than for HT or control. However, the titers of these autoantibodies were 
higher in HT patients, but there was no significant relation to insulin secretion and glucose tolerance at 
that moment and stage of autoimmune diseases. Arch Endocrinol Metab. 2017;61(3):361-6.
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INTRODUCTION
A utoimmune thyroid diseases (ATDs), represented by Graves’ disease (GD) and Hashimoto’s 
thyroiditis (HT) are very common, affecting up to 9% 
of population (1). It has been accepted that endocrine 
autoimmune diseases coexist in the same person and 
even in the same families. This association can be 
explained, in part, by a shared genetic background and 
is mainly linked to the HLA system and the CTLA-4, 
CD25, PTPN22 and FOXP3 genes (2).
The increased risk of an additional autoimmune 
disease in a subject with a primary diagnosis of ATD 
can be quantified (3).
Risk assessment of developing type 1A diabetes 
(T1AD) in adults can begin with the evaluation 
of genetics and autoantibodies to glutamic acid 
decarboxylase (GADA) and the protein tyrosine 
phosphatase antigen IA-2 (IA-2A), among other 
pancreatic autoantibody sera markers for T1AD (4,5). 
The risk of clinical disease is related to the titers (6,7) 
and the number of additional autoantibodies (8). 
However, the decreasing rate of beta-cell function is 
not homogeneous, and the subjects at risk for T1AD 
can express these autoantibodies for years prior to 
disease diagnosis (8). The metabolic abnormalities of 
the pre-diabetic period are not well understood. The 
presence of multiple pancreatic autoantibodies and 
impaired first phase insulin response (FPIR) are known 
to be strong risk factors to T1AD clinical development 
(9). Initial abnormalities in oral glucose tolerance tests 
(OGTTs) are frequently silent and can precede the 
diagnosis of T1AD (10). Both OGTT and intravenous 
glucose tolerance test (IVGTT) may also be modulated 
by insulin resistance (11).
The autoimmune process against islet beta-cells 
in adults is generally slow and can take years before 
clinical T1AD (12-15) appears. Also, there are reports 
on GADA patterns in autoimmune polyendocrine 
syndrome that can be different from those in sporadic 
T1AD patients. GADA has been detected in 6-13% of 
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GD and in 3-8% of HT patients (16-18). In a previous 
study, we evaluated the frequency of GADA in GD, 
HT and T1AD Brazilian patients (19) and found that 
despite the genetic diversity of our population, the 
frequency of GADA in Brazilians with these diseases is 
similar to their pairs from other countries.
Few studies have addressed the relation between 
islet-cell autoimmunity and glucose homeostasis in non-
diabetic ATD Brazilian patients. Here, we evaluated the 
prevalence of GADA and IA2A and their relation to 
first-phase insulin secretion and glucose tolerance in 
non-diabetic individuals with ATDs.
SUBJECTS AND METHODS
Patients were recruited between March 2001 and July 
2003. The study cohort (n = 324) was randomized from a 
southeast Brazilian population attending the outpatient 
endocrine clinic of a university hospital for follow-up of 
their ATDs. All were non-diabetic patients. In addition, 
as a control group, 93 blood donors, healthy subjects 
without T1AD, ATD or neither autoimmune disease’s 
first-degree relatives were studied.
All subjects gave informed written consent 
to participate. The study was approved by the 
Ethics Committee on Human Research of the 
University Hospital of São Paulo Federal University. 
GD was defined by the presence of biochemical 
hyperthyroidism with the following: I) diffuse uptake on 
a radionuclide scan/diffuse goiter on ultrasound scan; 
II) Graves’ ophthalmopathy; III) positive autoantibodies 
to the thyroid-stimulating receptor or IV) diffuse goiter 
on physical examination HT diagnosed by documented 
clinical and biochemical hypothyroidism requiring 
L-thyroxine replacement therapy and the presence of 
antithyroperoxidase (TPOAb) and antithyroglobulin 
antibodies (TgAb) and/or histologically by fine-needle 
biopsy of the thyroid. All patients were treated for thyroid 
disease and taking the following medicine: levothyroxine 
sodium, methimazole and radioiodine (I131) therapy.
Eleven euthyroid positive and twenty negative 
GADA and/or IA2A (a subgroup from the main ATD 
patient group) with a similar age, gender and BMI were 
submitted to an OGTT. All but one GADA/IA2Ab+ 
patient (due to technical problems) were submitted to 
an IVGTT (20) to evaluate the FPIR.
Baseline blood samples were obtained for 
measurements of glucose, insulin, thyroid hormones 
and autoantibodies.
Glucose was measured using the glucose 
hexokinase II enzymatic method.
Serum insulin was measured using a time-resolved 
fluoroimmunoassay (AutoDelfia Insulin-Perkin Elmer 
Life Sciences, Finland) with a reference range: 14.04–
158.4 pmol/L; the intra- and inter-assay coefficients of 
variation (CV) varied from 1.7% (serum insulin: 180.6 
pmol/L) to 2.4% (serum insulin: 33.0 pmol/L) and 
3.5% to 2.3%, respectively.
TPOAb and TgAb were measured in our laboratory 
using highly purified recombinant human TPO antigen 
(Fitzgerald Industries International, Inc, Concord, 
USA) and a human-purified Tg antigen employing 
flow cytometry (Luminex) (21). The cut-off limit was 
14 and 26 UI/ml for TPOAb and TgAb, respectively. 
TPOAb intra-assay CVs were 14.3% and 12.6% to mean 
values of 2.3 ± 0.33 and 621 ± 78 UI/ml, respectively, 
and inter-assay CVs were 33% and 20% to mean values 
of 1.8 ± 0.6 and 688 ± 139 UI/ml, respectively. Tg Ab 
intra-assay CVs were 9.2% and 9.6% to mean values of 
2.4 ± 0.22 and 811 ± 78 UI/ml, respectively, and inter-
assays of 36% and 19.6% to mean values of 2.3 ± 0.86 
and 905 ± 177 UI/ml, respectively.
TSH receptor antibodies (TRAb) were determined 
using a radioreceptor assay with reagents provided by 
BRAHMS AG (Henninsdorf, Germany). The normal 
value was < 10%, and the intra and inter-assay CVs were 
< 10% and 13.4%, respectively.
Serum TSH was measured using an 
immunofluorimetric assay developed in our laboratory 
(reference ranges: 0.3–5.0 mUI/L; intra- and inter-
assay CVs of 9.5% and 11.6%, respectively).
GADA 65 and IA2A were measured from frozen 
serum samples using a commercial radioimmunoassay 
kit RSR (UK, England). The results were expressed in 
U/ml. The cut-off limit for GADA was 1.72 U/ml 
and was 0.97U/ml for IA2A, which were estimated to 
be in the 99th percentile of the results obtained when 
we analyzed the sera from 194 healthy controls in our 
laboratory (22). The GADA intra and inter-assay CV 
were 3.58% and 4.9%, respectively. The IA2A intra- and 
inter-assay CVs were 4.3% and 3.4%, respectively.
The OGTT was performed according to the 
American Diabetes Association’s standards (23). IVGTT 
was performed in patients as previously described, after 
an overnight fast of 10 hours, between 7:00–9:00 am, 
and blood samples were drawn for measurement of 
glucose and insulin 5 minutes before and at time 0 and 
1, 3, 5, 10 minutes after an IV infusion of 25% glucose 
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(0.5 g/kg of body weight up to 35 g) (20). FPIR was 
determined as the sum of 1 plus 3-minute secretion 
during IVGTT.
Insulin resistance was evaluated using a homeostasis 
model assessment (HOMA) R index calculated from 
fasting plasma blood glucose and serum insulin 
concentration according to Matthews and cols. (24).
Statistical analysis
Statistical analysis was performed using SPSS version 
10.0 for Windows, SPSS Inc. A sample size was 
calculated to detect type 2 errors, taking into account 
the low prevalence of GADA and IA2A positivity in 
subjects with ATD. Data are expressed as the mean 
(SD) or as median and range. Data that were normally 
distributed were log transformed for analysis. Statistical 
differences in antibodies indices between groups were 
tested using ANOVA and Bonferroni. Homogeneity 
of variances was tested using Levene’s test. Differences 
in the frequencies of antibodies between HT, GD and 
controls were tested by chi-Square and Fisher’s test 
when appropriate. A p value < 0.05 was considered 
statistically significant.
RESULTS
The clinical features of GD (n = 181), HT (n = 143) 
and healthy control subjects (n = 93) are represented 
in Table 1.
GADA and IA2A were detected at 4.9% (16/324) 
and 0.7% (2/259), respectively, in the ATD patients. 
We did not find any patient with both antibodies. There 
was no difference between the clinical characteristics 
of GADA and/or IA2A positive and negative patients 
[(age 35 (22–68) vs 43 (16–77) years old, BMI (24.1 ± 
3.3 and 27.3 ± 5.4 kg/m2), such as disease duration 3.3 
(0.3–20) and 4.0 (0.1–39) years], respectively.
None of the 93 control group members was positive 
for GADA or IA2A.
Data on GD and HT individualized are shown in 
Table 1. Apart from the high variability of GADA titers 
in both ATD, the values in HT were significantly higher 
than in GD (p < 0.001) and controls (p < 0.001), but 
there was no difference between GD and controls 
(Figures 1 and 2).
In patients with positive pancreatic islet cell 
antibodies, we also analyzed GADA titers according 
to the length of time since the clinical diagnosis of 
ATD. We shared them in 4 groups: ≤ 1 yr., > 1 ≤ 
Table 1. Clinical and laboratory characteristics in ATD patients and control 
individuals
ATD Control
GD* HT**
N (F/M) 181 (151/30) 143 (132/11) 93 (53/40)
Age (y.o) 40 (16-71) 48 (16-77)a 28 (18-58)
Time from 
ATD 
diagnosis 
(years)
4 (0.2-35) 4 (0.1-39)
BMI (kg/m2) 26 ± 4 28 ± 6.2 25 ± 3.6
GADA (U/ml) 0.05 (0.0-324.89) 0.14 (0.0-57.85)b 0.0 (0.0-1.61)
IA2A (U/ml) 0.02 (0.0-1.46) 0.02 (0.02-1.53) 0.01 (0.01-0.77)
GADA+ (%) 13/181 (7.2) 3/143 (2.0) 0/93 (0.0)
IA2A+ (%) 1/146 (0.7) 1/113 (0) 0/30 (0)
TPOAb (U/ml) 72 (0.1-80) 222 (0.0-3116) 0.8 (0.1-133)
* GD: Graves’ disease. ** HT: Hashimoto’s thyroiditis.
Data are expressed as median (range) or mean ± SD.
a (HT vs GD and C; p < 0.01); b(GD vs HT; p < 0.01).
Figure 1. GADA level distribution in the groups. Values transformed to log
10
. 
** p < 0.001 (HT vs GD and controls) obtained by ANOVA.
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5 yr., > 5 ≤ 10 yr. and > 10 yrs. The GADA titers were 
70.7 ± 38.3, 61.2 ± 107.7, 16.5 ± 15.7, 4.7 ± 0.9 
U/ml, respectively, for these groups. The median 
figures of their ages were in the same order: 22 (22–
54), 29 (23–56), 43 (36–68), 44 (40–48) years old. 
Patients with less than five years of ATD seemed to have 
higher titers of GADA and be younger than the others.
Eleven positive and 20 negative pancreatic islet cell 
auto-antibodies euthyroid ATD patients with similar 
ages, genders and BMIs accepted being tested for FPIR, 
insulin resistance (HOMA-R) and OGTT (Table 2).
GD, GADA titers in HT patients were higher than 
those observed in GD patients. Nevertheless, GAD/
IA2 autoantibodies positivity per se does not seem to 
be associated with any disturbance in insulin secretion 
or glucose tolerance in euthyroid ATD patients at the 
time of this study.
GADA and IA2A frequencies were 4.9% and 0.7%, 
respectively, in the ATD patients. These frequencies 
were higher than those found previously in our healthy 
population (0.5% and 0.0%) (22) and demonstrated 
in similar patients in other studies (22-24). However, 
when the frequency of GADA in GD was compared 
to HT, the former (7.2%) tended to be slightly higher 
than the latter (2%). These data confirm our previous 
study when we found a higher prevalence of GADA in 
GD in a small group of patients with the same age and 
anthropometric clinical characteristics (19).
In Swedish patients, GADA was detected in 13% 
of newly diagnosed GD patients without clinical 
diabetes mellitus and in 3.4% of HT patients (18,25). 
In Japanese patients, GADA was found in 6% of GD 
and 7.9% of HT patients (17) although the time since 
thyroid disease diagnosis was not reported, and the 
patients were in different degrees of thyroid function. 
In our patients, the median time of thyroid disease 
clinical diagnosis was 4 years, with some of them with 
more than 30 years.
We observed that when ATD were pancreatic islet-
cell Ab-positive patients, they seemed to have thyroid 
disease for a shorter time and were younger, although 
the sample was too small to test this hypothesis 
statistically.
We found higher GADA titers in HT than GD 
patients despite the same age and thyroid-disease 
duration in both groups of subjects. The presence 
of higher GADA at the time of diagnosis in organ-
specific autoimmune diseases other than T1AD can 
be explained by the higher influence of an antigenic 
environment. Furthermore, it has been reported that 
the GAD65 protein is found in the brain and even in 
lower concentrations in the thyroid, pituitary, kidney, 
liver, adrenal, ovary and testes in addition to pancreatic 
islets, raising the possibility of triggering antibody 
production based on the polyclonal B-lymphocyte 
production in ATD patients (17). In fact, subjects with 
ATD also show a high prevalence of autoantibodies 
against non-thyroid specific antigens (26).
The relevance of GADA to T1AD development must 
be considered one step of the whole process, such as genes 
Table 2. Clinical and laboratorial features of positive (Ab+) and negative 
(Ab-) pancreatic islet-cell autoantibodies ATD patients analyzed in relation 
to βcell function and insulin resistance 
Ab+ Ab- p
Gender (F/M) 8/3 17/3
BMI (kg/m2) 24.3 ± 3.2 24.9 ± 3.2
GADA (U/ml) 14.2 (0.00-324.9) 0.06 (0.00-0.56) < 0.001
IA2Ab (U/ml) 0.2 (0.01-1.53) 0.0 (0.01-0.37) < 0.001
FPIR (pmol/L) 786.2 ± 534.0   984.0 ± 717.6
FPG (mmol/L) 4.78 ± 0.43  4.72 ± 0.47
2hPG (mmol/L) 6.07 ± 1.52 5.27 ± 1.31
HOMA-R 1.09 ± 0.6 1.33 ± 0.9
Data were expressed as median values at time of the last evaluation. 
Overall, there was not a significant difference 
between positive and negative GADA/IA2A euthyroid 
ATD patients in relation to first-phase insulin secretion, 
insulin resistance or oral glucose tolerance.
However, when they were individually analyzed, we 
saw that 27.2% (3/11) of the GADA/IA2A+ against 
5% (1/20) GADA/IA2A- showed low FPIR. Of these 
GADA/IA2A+/low FPIR, one had GD, with very 
high GADA titers (324.8 U/ml) and impaired fasting 
glucose (FPG = 6.83 mmol/L or 123 mg/dl), another 
had HT with low GADA titers (2.1 U/ml) and was 
overweight (BMI: 27 kg/m2) and the third subject 
had HT as well. Both with hypothyroidism had normal 
glucose tolerance. However, the GADA/IA2A-/low 
FPIR patient had GD and normal glucose tolerance.
DISCUSSION
In this study, we showed that the prevalence of 
GAD/IA2 autoantibodies in Brazilian, non-diabetic, 
euthyroid ATD patients is higher than in the healthy 
population studied. Despite the similar frequency of 
GAD and IA2 autoantibodies in patients with HT or 
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conferring susceptibility to or protecting from T1AD, the 
presence of others’ pancreatic antibodies, their titer levels, 
their persistence and the autoantibody epitope specificity. 
The autoimmune disease is the final phase of a process 
starting with auto recognition, passing through 
immunity with the appearance of autoantibodies and 
finally leading to cell destruction and autoimmune 
disease (27).
A study in a group of Japanese patients who had 
been diagnosed initially with non-insulin dependent 
diabetes mellitus (NIDDM) showed that those with 
higher GADA titers progressed rapidly to an insulin-
dependent state (28-30). However, in a study of 
stratification of diabetes risk in T1AD’s first-degree 
relatives, it was found that high titers of IA2A and IAA, 
though not GADA, were associated with an increased 
risk for clinical diabetes (29).
A study demonstrated that only the simultaneous 
presence of GADA and “classical” islet cell antibody 
(ICA) was associated with a loss of beta-cell function 
during follow-up and an increased risk of progression 
toward insulin dependency and low BMI (30).
We found that ATD patients with positive pancreatic 
islet cell Ab presented a downward tendency in the 
FPIR results besides normal FPG and glucose tolerance.
It has been shown that positive GADA HT patients 
had similar FPG and insulin concentrations than 
negative GADA subjects; however, when submitted 
to arginine injection, they showed a decline in the 
insulin secretory capacity and the glucagon response to 
arginine (25).
Insulin resistance in patients with islet autoimmunity 
could have a genetic-constitutional basis and might lead 
to the earlier appearance of hyperglycemia when beta-
cell function is compromised by autoimmune disease 
(31). In a recent study, this research group showed that 
T1AD relatives that were positive for islet antibodies 
and progressed most rapidly to diabetes had shown a 
subtle disturbance of insulin-glucose homeostasis years 
before the onset of symptoms, distinguished by greater 
insulin resistance for their level of insulin secretion. 
The degree of insulin sensitivity estimated by HR was 
similar between positive and negative GADA/IA2A 
groups and as expected, showed a positive relation with 
BMI (rS = 0.52; p = 0.0034).
This study was limited by a small sample of GADA/
IA2A-positive AITD patients in relation to FPIR 
and glucose tolerance and by the short follow-up of 
these patients.
In summary, the prevalence of GADA/IA2A was 
higher in non-diabetic ATD patients than in healthy 
controls. GADA prevalence was similar in HT and 
GD, but higher titers of these autoantibodies were 
found in the first. The degree of insulin resistance and 
glucose tolerance was similar between positive and 
negative GADA/IA2A euthyroid non-diabetic ATD 
patients. Moreover, we found only a tendency for low 
FPIR in GADA/IA2A-positive individuals. This may 
correspond to subclinical insulitis.
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